Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin

Author:

Giugliano Robert P.1,Keech Anthony2,Murphy Sabina A.1,Huber Kurt3,Tokgozoglu S. Lale4,Lewis Basil S.5,Ferreira Jorge6,Pineda Armando Lira7,Somaratne Ransi7,Sever Peter S.8,Pedersen Terje R.9,Sabatine Marc S.110

Affiliation:

1. TIMI (Thrombolysis in Myocardial Infarction) Study Office, Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts

2. National Health and Medical Research Council Clinical Trials Centre, Sydney Medical School, University of Sydney, Sydney, Australia

3. Third Department of Medicine, Cardiology, and Intensive Care Medicine, Faculty of Medicine, Sigmund Freud University, Vienna, Austria

4. Department of Cardiology, Hacettepe University Faculty of Medicine, Ankara, Turkey

5. Cardiovascular Clinical Research Institute, Lady Davis Carmel Medical Center, Haifa, Israel

6. Department of Cardiology, Hospital de Santa Cruz, Lisbon, Portugal

7. Amgen, Inc, Thousand Oaks, California

8. International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London, London, England

9. Ullevål and Medical Faculty, Oslo University Hospital, University of Oslo, Oslo, Norway

10. Deputy Editor, JAMA Cardiology

Publisher

American Medical Association (AMA)

Subject

Cardiology and Cardiovascular Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3